Health Trials

About this trial

This study intends to evaluate the efficacy and safety of cryoablation combined with Cardonilizumab and Bevacizumab in hepatocellular carcinoma with pulmonary metastases.

Eligibility criteria

Qualifiers

primary or recurrent HCC;

synchronous metastases (within one month after diagnosing of HCC) or asynchronous metastases (more than one month after diagnosis of HCC);

pulmonary-only metastases >5 and ≤10;

metastases diameter ≤ 5 cm;

Disqualifiers

under 18 years or over 75 years;

metastases >10

non-lung metastases;

incomplete clinical data;

Trial design

Treatments tested in this trial

  • Cadonilimab
  • Bevacizumab
  • Cryoablation

Treatment groups

80 Participants
are divided into 2 treatment groups

Locations

2
Sun Yat-sen University Cancer Center510000, GuanzhouGuangdong, China
Sun Yat-sen University Cancer Center510000, GuanzhouGuangdong, China

Sponsors and collaborators

Sun Yat-sen University

Lead sponsor

Source ClinicalTrials.gov